Evidence map›Paper›PMID 28454798›Full record

Trial reportAmerican heart journal2017

The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.

Carolyn Y Ho, John J V McMurray, Allison L Cirino, Steven D Colan, Sharlene M Day, Akshay S Desai, Steven E Lipshultz, Calum A MacRae, Ling Shi, Scott D Solomon and 3 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Baseline Characteristics of the VANISH Cohort.Circulation. Heart failure · 2019
    Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Hypertrophic cardiomyopathy.International journal of cardiology. Heart & vasculature · 2020
    Review
  11. Article
  12. Hypertrophic cardiomyopathy: genetics and clinical perspectives.Cardiovascular diagnosis and therapy · 2019
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Observational
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Carolyn Y HoBrigham and Women's Hospital, Boston, MA, USA. Electronic address: cho@partners.org.
John J V McMurrayUniversity of Glasgow, Glasgow, United Kingdom.
Allison L CirinoBrigham and Women's Hospital, Boston, MA, USA.
Steven D ColanBoston Children's Hospital, Boston, MA, USA.
Sharlene M DayUniversity of Michigan, Ann Arbor, MI, USA.
Akshay S DesaiBrigham and Women's Hospital, Boston, MA, USA.
Steven E LipshultzDepartment of Pediatrics, Wayne State University School of Medicine.
Calum A MacRaeBrigham and Women's Hospital, Boston, MA, USA.
Ling ShiNew England Research Institutes, Watertown, MA, USA.
Scott D SolomonBrigham and Women's Hospital, Boston, MA, USA.
E John OravBrigham and Women's Hospital, Boston, MA, USA.
Eugene BraunwaldBrigham and Women's Hospital, Boston, MA, USA.
VANISH trial investigators and executive committee
Brigham and Women's Hospital · USBoston Children's Hospital · USNew England Research Institutes · USUniversity of Glasgow · GBUniversity of Michigan · USWayne State University · US

Funding

Using Genetics For Early Phenotyping & Prevention of Hypertrophic CardiomyopathyP50HL112349 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, CAROLYN Y, SEIDMAN, CHRISTINE E · 2012 to 2017
$11.2M
NHLBI NIH HHS P50 HL112349
6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure. Studies in mouse models of sarcomeric HCM demonstrated that early treatment with an angiotensin receptor blocker (ARB) reduced development of LVH and fibrosis. In contrast, prior human studies using ARBs for HCM have targeted heterogeneous adult cohorts with well-established disease. The VANISH trial is testing the safety and feasibility of disease-modifying therapy with an ARB in genotyped HCM patients with early disease.

methodsA randomized, placebo-controlled, double-blind clinical trial is being conducted in sarcomere mutation carriers, 8 to 45 years old, with HCM and no/minimal symptoms, or those with early phenotypic manifestations but no LVH. Participants are randomly assigned to receive valsartan 80 to 320 mg daily (depending on age and weight) or placebo. The primary endpoint is a composite of 9 z-scores in domains representing myocardial injury/hemodynamic stress, cardiac morphology, and function. Total z-scores reflecting change from baseline to final visits will be compared between treatment groups. Secondary endpoints will assess the impact of treatment on mutation carriers without LVH, and analyze the influence of age, sex, and genotype.

conclusionsThe VANISH trial is testing a new strategy of disease modification for treating sarcomere mutation carriers with early HCM, and those at risk for its development. In addition, further insight into disease mechanisms, response to therapy, and phenotypic evolution will be gained.

Indexed as

AdolescentAdultAngiotensin II Type 1 Receptor BlockersCardiomyopathy, HypertrophicChildDouble-Blind MethodGenotypeHumansHypertrophy, Left VentricularMiddle AgedMutationSarcomeresValsartanYoung AdultAngiotensin II Type 1 Receptor BlockersValsartan

Identifiers

PMID28454798
PMCPMC5586211
OpenAlexW2588396622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.